SEC14L1 is a lipid-binding protein that functions primarily as a negative regulator of innate antiviral immunity. It inhibits RIG-I-mediated interferon-β production by binding to the RIG-I caspase activation and recruitment domain (CARD) and competing with MAVS/IPS-1/Cardif for RIG-I interaction, thereby blocking downstream signal propagation 1. The protein contains conserved CRAL/TRIO and PRELI-MSF1 domains required for its inhibitory function 1, and additionally interacts with cholinergic transporters VAChT and CHT1, potentially modulating acetylcholine transport 2. SEC14L1 has significant disease relevance in multiple malignancies. In breast cancer, SEC14L1 overexpression is a strong independent prognostic factor, with protein expression significantly associated with lymphovascular invasion, higher histological grade, HER2 positivity, and shorter survival 3. In prostate cancer, SEC14L1 expression correlates with aggressive features including high Gleason score and early PSA recurrence, particularly in TMPRSS2:ERG-negative tumors 4. SEC14L1 overexpression is also notably frequent in endometrial serous carcinoma 5. A genome-wide haplotype association study identified SEC14L1 variants associated with monoclonal gammopathy of unknown significance, suggesting involvement in innate immunity pathways relevant to multiple myeloma susceptibility 6.